Alliance Pharma (CRO)
Alliance Pharma is a Contract Research Organization (CRO) specializing in Drug Metabolism and Pharmacokinetic (DMPK) and bioanalytical services for both small and large molecules. Our extensive and diverse industrial experience includes:
- New drugs, metabolites or generic drug assays
- Small molecule LC-MS/MS analysis
- Large molecule immunoassays
- Cell based assays
- Small molecule metabolite profiling and identification
- Pharmacokinetic modeling and design
- Large molecule and biosimilar characterization services
It is our goal to help you through the process of taking your drug from pre-clinical/clinical trials to market as fast and as problem-free as possible. We work closely with our clients allowing them full access to data so they feel as if they are walking through their project development with us, step-by-step.
We share the same level of involvement and commitment as our clients and are dedicated to building a collaboration that enables efficient development of life-changing products while assuring scientific, regulatory and data integrity. Because we invest in each project, we take responsibility and are accountable for the performance and success of our projects.
More recently, Alliance Pharma closed on the purchase of Drug Development Solutions (DDS), a U.K.-based bioanalytical and material science testing contract research organization (CRO), from LGC. Alongside Alliance’s bioanalytical expertise, DDS adds an unrivalled breadth and depth of expertise in bioanalysis and analytical and materials science as well as two state-of-the-art analytical labs in Cambridge (Fordham), U.K., and Sandwich, Kent, U.K.
We fully realize and respect our client’s need for uncompromised regulatory compliance and take every step to ensure that we follow all regulations. Quality is essential to our clients, we are committed to bring scientific and laboratory excellence to each project we work on.
